Objective An unintended consequence of cystic fibrosis (CF) newborn screening (NBS) is the identification of infants with a positive NBS test but inconclusive diagnostic testing. These infants are classified as CF transmembrane conductance regulator-related metabolic syndrome (CRMS) in the US and CF screen positive, inconclusive diagnosis (CFSPID) in other countries. Diagnostic and management decisions of these infants are challenges for CF healthcare professionals and stressful situations for families. As CF NBS has become more widespread across the world, increased information about the epidemiology and outcomes of these infants is becoming available. These data were reviewed at the 2015 CF Foundation Diagnosis Consensus Conference, and a harmonized definition of CRMS and CFSPID was developed.
D
uring the development of the 2008 cystic fibrosis (CF) diagnosis consensus guidelines, it was recognized that the increased implementation of newborn screening (NBS) had led to a new and complex diagnostic dilemma of infants with abnormal NBS tests but inconclusive sweat tests and/or DNA test results. 1 Rather than address this complex situation in the diagnostic guidelines, a separate CF Foundation consensus conference was convened to address 3 CRMS is the term used in the US to describe infants with elevated immunoreactive trypsinogen (IRT) levels, but with insufficient sweat chloride or genetic data to support a diagnosis of CF. Although this condition is not a metabolic disorder, the designation metabolic syndrome was established in part to have an International Statistical Classification of Diseases and Related Health Problems, Ninth Revision medical code (277.9) for US healthcare delivery system follow-up and billing purposes. However, CRMS has not been accepted in Europe and some other countries because of concern about the appropriateness of the term and a feeling that it was difficult for families to understand. Thus, a similar term, CF screen positive, inconclusive diagnosis (CFSPID), was developed in a Delphi process 4 by the European CF Society (ECFS) Neonatal Screening Working Group and introduced recently in Europe as an alternative to CRMS. 5 The planning committee for the 2015 Diagnosis Consensus Conference recognized that with the increasing use of CF NBS worldwide, CRMS and CFSPID have become important aspects of the CF diagnostic process. Therefore, the conference included a session to review recently published and unpublished data on populations with CRMS and CFSPID. An important goal of the conference was to develop a consensus to unify the definition of CRMS and CFSPID that could allow for collection of data from populations around the world and increase our understanding of the epidemiology and outcomes of CRMS/CFSPID. At the conclusion of the conference, consensus recommendations were crafted and agreed upon by electronic survey ( Table I) .
Harmonization of US and ECFS Terminology
In the US, the expert consensus panel specifically created a term that did not imply the infant has CF, whereas still acknowledging that these infants required follow-up by CF specialists. 3 
CRMS (International Statistical Classification of Diseases and
Related Health Problems, 10th Revision code E88.89) was defined as an infant with hypertrypsinogenemia at birth who is asymptomatic, and who has either: (1) persistently intermediate sweat chloride levels (30-59 mmol/L if age <6 months or 40-59 mmol/L if age ≥6 months) and fewer than 2 CFcausing CFTR mutations; or (2) sweat chloride concentration <30 mmol/L and 2 CFTR mutations with 0 to 1 known to be CF-causing.
In Europe and some other countries, especially when international coding is not required for healthcare delivery, expert consensus differed slightly on how to define this group. In the initial ECFS consensus process, 4 it was recommended that these infants should not have a designation, but in the second exercise 5 years later, 5 it was clear that the majority of respondents believed a designation was needed. In the subsequent voting exercise (including CRMS as an option), there were 2 clear favorites: CF inconclusive diagnosis and CFSPID. An expert panel decided to amalgamate the 2 terms, and CF screen positive, inconclusive diagnosis (CFSPID) reached high levels of agreement in the subsequent round of the Delphi exercise, creating a category for infants who are asymptomatic, with hypertrypsinogenemia at birth, 5 and have either: (1) 0 or 1 CFTR mutations, plus intermediate sweat chloride (30-59 mmol/L); or (2) 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences, plus a normal sweat chloride (<30 mmol/L).
The differences between the definitions of CRMS and CFSPID are minor and resolved by the improved characterization of CFTR mutations as disease-causing by the CFTR2 project. The CF Foundation recognizes that CFSPID is a term that may be helpful in describing this complex situation to parents and families. However, the term CRMS will continue to be required for entry of this group of individuals into the US healthcare system. Recognizing the 2 groups as 1 will CFTR mutations that have been shown to be non-CFcausing should not be considered when applying the definition. Also, note that infants with CRMS/CFSPID who have sweat chloride levels of 30-59 mmol/L may have 0, 1, or 2 CFTR mutations, as long as they do not have 2 CF-causing mutations.
Risks and Benefits of Labels
There are risks to classifying infants with CRMS/CFSPID, including anxiety in parents and families, and increased healthcare costs because of extensive and potentially expensive diagnostic evaluations. Currently, despite guidelines, there are different practices regarding the extent, detail, and frequency of these evaluations. A detailed work-up, including DNA sequencing and additional tests, such as nasal potential difference measurements and intestinal current measurements, may resolve the diagnosis of CF in some cases, but certainly many cases will continue to remain inconclusive, despite extensive testing.
Overall, however, creation of a category for these infants is considered beneficial because it allows these infants who cannot be clearly diagnosed with CF but may remain at risk of CF to be followed so that treatment, if needed, can be initiated quickly for optimal outcomes. Further, it allows for epidemiologic studies to be performed that will help define the disease risk and outcomes for this group of individuals.
To provide additional guidance, the consensus conference reviewed recent data from Europe, Canada, Australia, and the US on frequency of occurrence and outcomes of infants categorized as CRMS/CFSPID. These studies were used to generate recommendations for further testing in CRMS/CFSPID, including genetic and ancillary CFTR functional studies that may help diagnose CF or identify infants likely to develop clinical features of CF (Table I) .
Prevalence, Clinical Features, and Outcomes of CRMS/CFSPID
Nutritional indices in this population are generally good. An analysis of data on infants with CRMS reported during 2010-2012 to the US CF Foundation Patient Registry (CFFPR) showed that almost all infants with CRMS in the CFFPR had pancreatic-sufficiency, consistent with other recent studies of CRMS. 6 However, a higher-than-expected rate of respiratory cultures may be positive for bacteria typically associated with CF [6] [7] [8] [9] ; for example, in the CFFPR study, 11% of the infants in the group with CRMS had at least 1 positive Pseudomonas aeruginosa respiratory culture during the first year of life, a proportion higher than that reported in the population without CF, underlining the need for these infants to be followed. 6 Although it is important to ensure that these infants are monitored, the application of a CF diagnosis should be made with much thought, taking into account the implications for the infant and family with increased healthcare costs and raised anxiety. Follow-up requires a careful balance between surveillance and readiness to diagnose with CF and appropriately treat. Several recent studies (Table II) have provided information about CRMS/CFSPID prevalence and outcomes and longitudinal studies show that these infants do have a small risk of developing CF over time. The results of these studies, described briefly below, can help provide guidance on determining how this group should best be monitored.
CRMS/CFSPID Characteristics in US CF Foundation Patient Registry
The CFFPR collects data from all the accredited CF care centers in the US. In 2010, CRMS was added as a diagnostic category, . ‡Number of infants with CF inferred based on reported annual rate of new diagnoses and timespan of study. §CRMS definition was slightly different from CRMS/CFSPID. ¶Diagnosed through clinical signs and symptoms of respiratory disease or PI. Eight were diagnosed through respiratory symptoms. **R117H(7T) as their second mutation with a class 1, 2, or 3 mutation as the first.
and Ren et al 6 reported the outcomes in infants with CRMS from 2010 to 2012. A total of 1540 infants met the diagnostic criteria for a CF diagnosis in that timeframe, and 309 met the criteria for CRMS (5:1). However, 40.8% of infants that fit a strict CRMS definition were actually classified as CF by the recording CF center, and 13 states entered a CF diagnosis inappropriately for at least 10% of their infants. Based on definitions established in the guidelines, 8 infants placed into the CRMS category should actually have been diagnosed with CF. It may be possible that clinical data not entered into the Registry affected the decision to classify an infant as CF. However, it is also possible that there is some confusion or disagreement with consensus guidelines. A more consistent approach to classification is important to reduce variations in CRMS/CFSPID incidence that can have a significant impact on registry data quality and epidemiology research efforts.
Growth and nutritional indices in the group with CRMS were normal, but some infants had positive respiratory cultures for CF associated pathogens, such as P aeruginosa (10.7%) and Stenotrophomonas maltophilia (9.4%). The genotype c.1521 _1523delCTT (legacy: F508del)/c.[350G>A;1210-12 [7] ] (legacy: R117H;7T) was present in 26% of infants with CRMS, reflecting the variable phenotype associated with the R117H mutation. There were more Hispanic and non-White infants in the group with CRMS compared with the group with CF (19.1% vs 12.5% and 11.7% vs 6.5%, respectively). The relatively higher proportion of Hispanic infants in the group with CRMS, however, could be due to the large numbers of infants reported with CRMS from California, which has a large Hispanic population and uses an NBS algorithm with a greater probability of CRMS detection. The CFFPR higher proportion of African American infants in the group with CRMS could reflect the fact that African American infants tend to have higher IRT levels, 12 and CF itself is less common in the African American population, leading to a higher number of false-positive NBS tests.
CRMS/CFSPID in Wisconsin
Investigators from Wisconsin reported their experience with CF and CRMS in a cohort of 376 patients. 7 Most of these patients were diagnosed through NBS, but some were referred from neighboring states or came to attention through clinical features suggestive of CF. These patients were divided into 3 groups: CF, CRMS, and CFTR-related disorder (CFTR-RD). 13 CFTR-RD was defined as an infant or child with clinical features of CF in a single organ system and who had: (1) an intermediate sweat chloride concentration and/or 2 CFTR mutations of which no more than 1 was known to cause CF; or (2) a sweat chloride concentration below the upper limit of normal for age. There were 300 patients with CF (80% of the total), 57 infants with CRMS (15%), and 19 patients with CFTR-RD (5%). The median IRT level was significantly higher in the group with CF compared with the groups with CRMS and CFTR-RD (171 ng/mL vs 94 ng/mL in CRMS and 106 ng/ mL in CFTR-RD; P < .001). Similarly, the mean sweat chloride concentration was also higher in patients with CF compared with these other groups (105 mmol/L vs 35 mmol/L for CRMS and 43 mmol/L for CFTR-RD; P < .001). Patients with CF were significantly more likely to have pancreatic insufficiency (83% vs 0%; P < .001), failure to thrive (28% vs 2%; P < .001), and a respiratory culture positive for P aeruginosa (80% vs 39%; P < .001). Fourteen of the infants with CRMS had a sweat chloride concentration <30 mmol/L; mutation analysis revealed that 10 infants had F508del on 1 allele and 13 had R117H-7T/9T.
CRMS/CFSPID in California
The large, diverse California population provides additional insight into the population with CRMS. 10 California uses a 40-mutation genetic panel, specific to the state's population, in all infants with high IRT. Infants with 2-panel mutations are screen positive. Infants with only 1 California-panel mutation identified undergo gene scanning and sequencing, and only those with 1 or more additional CFTR mutations are considered to have a positive newborn screen. From 2007 to 2012, a total of 2 573 293 newborns were tested; 345 were diagnosed with CF (20 of whom were initially considered to have CRMS); 553 were categorized as CRMS (not including the 20 who were later given a CF diagnosis), and 1617 were designated healthy carriers. In addition, 28 infants were later diagnosed with CF following false-negative NBS results. Thus, in California, there was a rate of approximately 2 infants with CF for every 3 infants diagnosed with CRMS.
It is likely that the gene sequencing required by the California program is at least partially the cause of the identification of large numbers of infants categorized as CRMS, and it is useful to examine whether this results in an overall benefit to population health. Some of the infants are labelled as CRMS because of the presence of novel CFTR mutations whose disease-causing potential is unclear. Over the first 3 years of the California NBS program, 55 novel CFTR variants were identified in the 524 infants with 2 mutations detected.
14 Of the 424 infants with adequate follow-up, novel CFTR variants were detected about equally in the group of infants diagnosed with CF (14/110, 12.7%) during the 3-year study compared with those who stayed in the group with CRMS (28/279, 10%). Thus, in this population, the detection of novel CFTR variants resulted in the identification of 14 additional children with CF at the "cost" of adding another 28 children to the CRMS category who may not eventually become symptomatic. Further analysis of these infants has shown as expected that infants with a non-CF-causing CFTR mutation have benign outcomes, but that those with mutations of varying clinical consequences can potentially develop CF. 15, 16 It is likely that factors other than CFTR play a role in this, but these are unclear at this point and only large long-term studies will provide clarity.
In the first 5 years of the California NBS program, progression from CRMS to a CF diagnosis because of clinical presentation has occurred in a relatively limited number of infants: In 20 infants with CRMS (5.8%), a diagnosis of CF was made due to 1 or more clinical symptoms, including failure to thrive/ gastrointestinal involvement, respiratory involvement, or P aeruginosa infection (n = 7; 29%). Two of the 24 patients (8%) eventually had sweat chloride >60 mmol/L levels just above the diagnostic cut-off.
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In New South Wales, Australia, infants are categorized as CFSPID if they have a high IRT on NBS, 1 copy of F508del, and an intermediate sweat chloride concentration of 30-59 mmol/L. A retrospective long-term follow-up of 29 infants in this group revealed approximately one-half (n = 14) were eventually diagnosed with CF and referred to as "delayed CF," although the course of CF was milder compared with NBSpositive CF cases. 11 From this study, the estimated risk of a future CF diagnosis is 48%, much higher than that found elsewhere in the literature (8%-15%). However, many of the infants were diagnosed as delayed CF based on nonspecific respiratory symptoms, such as cough.
At the 2015 CF Diagnosis Consensus Conference, investigators from Victoria, Australia, presented their experience involving 111 infants with positive NBS results (high IRT, 1 CFTR mutation) and sweat chloride concentration of 30-59 mmol/ L. The clinical practice at that time (1994-2014) was to perform clinical assessment at 4-6 weeks of age, fecal elastase measurement, and extended CFTR mutation analysis. The infants were seen again at 6-12 months of age, and sweat testing was repeated. Infants with sweat chloride concentration <40 mmol/ L, only 1 CFTR mutation found, and no clinical features of CF were considered carriers and referred for genetic counseling only. Infants with clinical features of CF or with a diagnostic sweat chloride concentration (≥60 mmol/L) or in whom a second CF-causing mutation was found were referred for CF care. Individuals who continued to display sweat chloride concentration of 30-59 mmol/L, or found to have a second CFTR mutation of unknown significance or indeterminate clinical features, were not considered to have CF and were referred for annual clinical assessment, with a repeated sweat test ordered when they reached 5 years of age. Over the 20-year study period, 15 children received a diagnosis of CF and 96 were determined to be healthy carriers. In the group of individuals with intermediate sweat chloride concentrations, the higher the value, the more likely the individual would eventually receive a CF diagnosis. The Victoria experience showed that the vast majority of these children never received a CF diagnosis, but a small minority did.
CRMS/CFSPID in Canada and Verona, Italy
A prospective, longitudinal study was performed in collaboration between Canada and the CF center in Verona, Italy. They identified 1-2 subjects with CFSPID for every 3 infants with CF. A study reported on the first 3 years' health outcomes of 82 individuals categorized as CFSPID compared with the health outcomes of 80 infants with CF diagnosed through NBS. 8 CFTR mutation rates did not differ between the CF and CFSPID groups; extensive gene analysis showed that 2 CFTR mutations were present in 96.3% of individuals in the group with CFSPID, compared with 92.5% in the group with CF. P aeruginosa and Staphylococcus aureus were isolated in 12% and 40%, respectively, of subjects with CFSPID. Although this was significantly less than in patients with CF (31% P aeruginosa and 71% S aureus), the frequency is higher compared with a healthy non-CF population. 17, 18 In the CFSPID group, there was a slight increase in sweat chloride concentration throughout the first 2-3 years of life. In 9 of the 82 children in the group with CFSPID (11%), CF was eventually diagnosed through abnormal sweat chloride results, reclassification of their CFTR mutations as CF-causing, or a combination. Infants that converted from the CFSPID category to a CF diagnosis had significantly higher serial sweat chloride levels (P < .0001) and serum trypsinogen (P = .009) levels than did individuals who remained in the CFSPID group. The authors demonstrated that sweat testing at age 2 years provided the clearest differentiation between infants who were likely to develop a positive sweat test and be reclassified as having CF compared with those who were unlikely to do so.
CRMS/CFSPID in France
The French CF NBS algorithm utilizes a 30-mutation genetic screen, specific to their population, in all high-IRT infants. Between 2002 and 2014, over 10 million babies were screened. A total of 1765 infants met the diagnostic criteria for a CF diagnosis in that timeframe, and 280 met the criteria for CFSPID based on the available US definition of CRMS (CF:CFSPID, 6.3:1.0). R117H was identified in 58% of infants labeled CFSPID, all with a polypyrimidine variant in intron 8 T7 in cis. The estimated risk of a future CF diagnosis has not been yet evaluated. A prospective nutritional, pulmonary, and diagnosis assessment of a national matched cohort CF/CFSPID is underway.
Recommendations for Follow-Up of Infants with CRMS/CFSPID
Following a review of data presented at the consensus conference, recommendations for follow-up of CRMS/CFSPID infants were developed by electronic survey of the consensus committee ( Table I ). The committee determined that when an infant is classified as CRMS/CFSPID, a clear explanation must be given to the parents and primary care provider (PCP). 3 Genetic counselling should be offered to the family. The children should undergo at least 1 repeat sweat chloride test at the CF center, and extended CFTR genetic analysis. In addition, second-tier CFTR functional analysis (nasal potential difference or intestinal current measurement) can be considered and performed by centers with expertise in these tests. Other clinical assessments, such as measurement of fecal elastase activity, can be performed as clinically appropriate. Parents and PCPs should understand that children classified as CRMS/CFSPID must be followed by a specialized CF care physician because some will develop manifestations of CF disease (Appendix; available at www.jpeds.com). However, there are currently not enough data to help stratification of the individuals at risk for developing CF disease. CF care centers should follow strict infection control guidelines for infants with CRMS/CFSPID to minimize exposure to individuals with CF and, thus, potential transmission of pathogens. Although guidelines for management of CRMS/CFSPID have been published, they are based on limited data. 3, 4 February 2017
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It was apparent to the consensus committee that further research is needed to determine the prognosis and best practices for frequency and duration of follow-up of the infant with CRMS/CFSPID. To facilitate this, parents should be advised on the need to provide consent to include data on their infants in patient registries.
Discussion
In the past few years, several studies of CRMS and CFSPID have been reported from across the world. Although they vary in terms of patient characteristics, sample size, and study design, some common themes have emerged. CRMS/CFSPID is a relatively common outcome of CF NBS, and CF clinicians and PCPs need to be prepared to counsel families with these infants. The majority of these infants do not go on to develop clinical CF, but in some infants, the diagnosis of CF is eventually made through an increase in the sweat chloride concentration into the CF diagnostic range, or through reclassification of an infant's CFTR mutation as disease-causing based on increased knowledge of CFTR genetics. In addition, infants may be diagnosed subsequent to the development of clinical features that are concerning for CF. Because respiratory symptoms, such as cough and wheeze, are very common in infants and young children without CF, interpreting their significance in children with CRMS/CFSPID is challenging. To avoid potential transmission of CF-related respiratory pathogens, exposure of infants with CRMS/CFSPID to individuals with CF should be minimized during medical evaluation and follow-up.
Current studies suggest that most of the infants with CRMS/ CFSPID do not develop disease symptoms in a 3-year followup period. However, there is a lack of longer term outcome data. Experiences from diagnosing adolescents and adults with CF or a CFTR-related disorder suggest that disease symptoms on these individuals can become apparent later in life. Studies of large cohorts of infants with CRMS/CFSPID are essential to better understand the relationship between CRMS/ CFSPID, CF, and CFTR-RD and to provide more information to CF caregivers to counsel families of these infants. Families need to be well-informed of the increased risk for these infants as they grow. Some infants with CRMS/CFSPID may develop respiratory symptoms and acquisition of CF-typical respiratory pathogens. However, because of lack of data, we currently do not know how many of those will go on to develop CFTR-RD or CF.
A harmonized definition will facilitate research into the frequency and clinical outcomes of these infants, which should address a number of concerns:
• Will these patients remain free of significant symptoms, or will they demonstrate increasing pathology, "phase shifted" by a few decades? • What factors are involved or promote this development and progression of pathology? • Do the current recommendations for management, including testing and follow-up, provide the optimal balance between monitoring and detecting development of CF disease while not over medicalizing infants with CRMS/CFSPID? • Should the CF care team adopt a more proactive approach for this infant or is the reactive approach advocated in current recommendations appropriate? • What is the psychological impact of designating a potentially healthy individual with CRMS/CFSPID? • What is the cost to the healthcare system of follow-up for infants with CRMS/CFSPID, and how should this be considered in the financing of CF NBS? • When can we release an individual from a designation of CRMS/CFSPID? Even if they are asymptomatic as infants and children? • What is the true risk of these infants developing singleorgan disease as an adult consistent with a designation of CFTR-RD?
These important questions need answers if we are to monitor this group of children optimally. However, this consensus conference focused on diagnosis and definitions, not management. Thus, although the definitions of CRMS and CFSPID should be harmonized as described above, no recommendations on management were made at the consensus conference other than follow-up diagnostic testing. We appreciate that current management of CRMS/CFSPID may differ between the US and other countries. CF Foundation guidelines for the management of infants with CRMS were published in 2009, and it is likely that they will be revised in the near future to reflect the additional knowledge gained since that time. ■
